Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs
Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents
About this trial
This is an interventional treatment trial for Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents focused on measuring Ayurvedic formulation, type 2 diabetes mellitus, secondary failure to oral hypoglycemic agents, antidiabetic
Eligibility Criteria
Inclusion Criteria:
Secondary failure to Oral Hypoglycemic Agents was diagnosed if the patient had HbA1c levels > 8.5% even after supplementation of maximal dose of a combination of a sulphonylurea (15 mg glybenclamide or 160 mg gliclazide or 15 mg glipizide) and metformin 1500 mg/day.
Exclusion Criteria:
Patients with ketosis, diabetes related complications, hepatic or renal disease, pancreatitis, cardiac problems, uncontrolled hypertension, malnutrition and severe immune deficiency
Sites / Locations
- Jyoti Clinical and Pathological Laboratory
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
CORN STARCH
Mersina, Diet and exercise